Scienmag

MAY 18, 2021

(Boston)–Researchers from Boston University School of Medicine (BUSM) report the formation of human cells containing a green fluorescent protein or GFP (one of the most important proteins in biology and fluorescence imaging) genetically fused with two interferon stimulated genes (ISGs), namely Viperin and ISG15.

Immune Response 41

Immune Response Reagent Research Protein 41

Delveinsight

AUGUST 26, 2021

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 Billion. Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. was swooped up by Real Chemistry in January.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

Cloudbyz

MARCH 6, 2024

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. This candidate, derived from a person’s own genetically modified cells, aims to restore the Gag-specific CD4+ T cell response in those receiving antiretroviral therapy.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

XTalks

APRIL 26, 2021

This is because there are thousands of genes in malaria parasites compared to only about a dozen or so in coronaviruses. Moreover, a very strong immune response is needed to fend off the disease. That’s a real technical challenge,” said Hill, “The vast majority of vaccines haven’t worked because it’s very difficult.”.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

pharmaphorum

NOVEMBER 25, 2021

A vaccine delivered by subcutaneous injection targeting tau – a protein which forms tangles that are another feature observed in AD brains – is also being studied by drugmaker Johnson & Johnson in partnership with AC Immune in a phase 1 study. Its main objective is gauging the safety and tolerability of the vaccine.

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

XTalks

MARCH 2, 2021

It is based on the insertion of a portion of the gene coding for the spike protein of SARS-CoV-2 into a replication-inactive adenovirus-associated virus (AAV). The AAV serves as a vector to carry the gene into cells from which the spike protein fragment is made to elicit an immune response.

Vaccination 98

Vaccination Vaccine Trials Clinical Trials 98

Delveinsight

DECEMBER 22, 2020

FDA Puts uniQure’s Hemophilia B Gene Therapy on Leash. In a recent, uniQure faced backlash after its hemophilia B gene therapy got hit with clinical hold by the USFDA. . It substantially increased the production of the blood-clotting protein factor IX, which is the factor missing for hemophilia B patients, in all the enrolled patients.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

XTalks

MAY 1, 2023

Last week, the US Food and Drug Administration (FDA) granted accelerated approval to Biogen’s Qalsody (tofersen) for the treatment of adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This makes Qalsody the first approved treatment to target a genetic cause of ALS.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

Pharmaceutical Technology

JULY 29, 2022

Bivalent vaccines work by stimulating an immune response against two different antigens, whereas monovalent vaccines only target one antigen. 5 spike protein components to their current vaccine compositions to create a two-component booster, so that the modified vaccines can potentially be used from later this year.

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

Delveinsight

DECEMBER 3, 2020

Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. Janssen buys a gene therapy asset. Janssen buys a new gene therapy aimed at reversing a severe disease, from Hemera Biosciences.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Delveinsight

AUGUST 6, 2020

ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus. Taysha raises USD 95 Million to take 4 CNS gene therapies into the clinic.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

pharmaphorum

MAY 18, 2021

.” The interim phase 2 results show that two doses of the plant-derived jab stimulated neutralising antibody levels that are around 10 times higher than those in a panel of sera from patients recovering from COVID-19, with a similar response seen in adults and the elderly.

Vaccination 64

Vaccination Vaccine Immune Response Gene Sequencing 64

Delveinsight

SEPTEMBER 23, 2021

Boehringer stated that the Abexxa’s generation aims at cancer-specific proteins situated throughout the mobile versus proteins at the mobile membrane broadening the selection of possible cancer antigen objectives. 858’s drug candidates include proteins, which regulate RNA and immune response.

RNA 61

RNA Gene Therapy Gene Protein 61

XTalks

SEPTEMBER 17, 2020

Inherited mutations in the SLC3A1 and SLC7A9 genes cause cystine to be abnormally transported within the kidney leading to cystinuria. Dietary changes, including restriction of salt and animal protein, are also recommended. Mutations in the gene encoding ?-Gal Prevalence: ABCG5 gene mutation: 1 in 2.6 galactosidase A (?-Gal

Trials 98

Trials Gene Hormones Clinical Trials 98

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. The combination appears to work by activation of the tumour-suppressing protein p53, they announced. The gene TP53 produces the protein p53, a known tumour suppressor.

Research 52

Research Protein Clinical Trials Clinical Trials 52

Roots Analysis

AUGUST 23, 2024

Unveiling The Potential of mRNA Technology mRNA is a single-stranded molecule that relays the genetic instructions needed to make proteins from DNA in the cell nucleus to ribosomes. Ribosomes are cellular machines that read mRNA sequences and produce proteins. There are several advantages to approaching vaccination this way.

Protein 40

Protein Vaccination Vaccine Immune Response 40

pharmaphorum

AUGUST 18, 2021

To plug that gap, the team collected demographic and clinical data and combined that with analysis of whole blood transcriptomes – the mRNA coded for by genes that in turn is used to produce proteins – metabolic profiling of plasma and red blood cells, and mapping of subjects’ immune cells and cytokines.

Immune Response 52

Immune Response Protein Research Gene 52

The Pharma Data

DECEMBER 23, 2020

Of the 17 mutations, eight are in the gene that encodes the spike protein. One is N501Y, which has been previously shown to increase how the spike protein binds to the ACE2 receptor. Gene Pathway Linked to Schizophrenia. A Better Understanding of the Coronavirus Spike Protein. Two are particularly concerning.

Research 52

Research Protein Gene Vaccination 52

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

Pharmaceutical Technology

MARCH 24, 2023

Fox says adjuvant protein subunit vaccines can be a safer approach compared to live attenuated virus vaccines as there is a minimized risk of developing side effects. Using an adjuvant with an antigen can give specific tailored and potent immune responses, he adds.

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

The Pharma Data

SEPTEMBER 30, 2021

Liu’s team was ready to encapsulate the agonist of the stimulator of interferon genes (STING) within liposomal particles to yield the adjuvant named NanoSTING. The function of the adjuvant is to market the body’s immune reaction. “Equitable distribution requires vaccines that are stable which are often shipped easily.

Vaccination 52

Vaccination Vaccine Immune Response Licensing 52

The Pharma Data

JUNE 26, 2021

The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Source link: [link].

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Shots on goal in the fight against COVID-19. About Translate Bio.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Find Me Cure

OCTOBER 13, 2019

HER2 is a protein that plays an important role in cancer cell growth and is found on the surface of cancer cells in a very high quantity in about 10-20% of breast cancers. PI3 kinase is an enzyme controlled by the PIK3CA gene, a gene that is often mutated in breast cancer, which in turn causes the cancerous tumour to grow. .

Development 52

Development DNA Clinical Trials Clinical Trials 52

The Pharma Data

JULY 6, 2021

Enrolment is currently underway for a pivotal Phase 3 trial for AL001 in people at risk for or with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). AL001 and AL101 are novel human monoclonal antibodies that elevate levels of progranulin by blocking the sortilin receptor responsible for progranulin degradation.

Genetics 52

Genetics Gene Antibody Development 52

The Pharma Data

OCTOBER 27, 2020

The Massachusetts-based biotech is investing in their proprietary “Gene Traffic Control” system, which tells the cells when to express which genes where and in what order within the chromatin regulatory system. Foghorn boomed onto the NASDAQ with a $120 million IPO , surpassing its original expectations by $20 million. AavantiBio .

Gene 52

Gene Gene Therapy Medicine Development 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The BET inhibitor worked by increasing beta-3 tubulin (TUBB3), a protein found in brain metastases. Brown fat generates heat in response to low temperatures due to its expression of the protein UCP1.

Vaccination 53

Vaccination Vaccine Research Trials 53

Roots Analysis

MAY 21, 2024

LNPs comprise of a lipid bilayer that surrounds a hydrophobic core, which can be loaded with therapeutic agents ( such as drugs, genetic material and proteins ). Gene Therapies: LNPs have the ability to effectively deliver nucleic acids, including small interfering RNA (siRNA), messenger RNA (mRNA), and plasmid DNA to the target cells.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

XTalks

JUNE 9, 2022

When a child born from parents with FH genes, inherits one FH gene from each parent, they might develop homozygous familial hypercholesterolemia (HoFH). Evkeeza works by binding to and blocking the function of ANGPTL3, which is a protein that plays a role in lipid metabolism. This disease can also result in early fatalities.

Trials 52

Trials Antibody Genetics Gene 52

pharmaphorum

NOVEMBER 2, 2021

The more targeted, bispecific functionality of bsAbs broadens the reach of antibody-mediated therapies against both solid and haematological cancers, creating novel approaches that can induce a tumour-specific immune response, target immune checkpoints, or improve payload delivery to tumour cells (Fig.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

DECEMBER 20, 2020

It is an optimized, non-chemically modified mRNA that codes for the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. Pfizer and BioNTech announced additional data on neutralizing antibody and T-cell responses from their Phase I/II trial of their COVID-19 vaccine conducted in Germany. Non-COVID-19-Related.

Trials 52

Trials Gene Therapy Vaccination Vaccine 52

The Pharma Data

DECEMBER 27, 2020

The drug is a topical ointment applied to the lower lid to address the build-up and shedding of proteins at the opening of the Meibomian gland. TSHA-101 is an investigational gene therapy designed to deliver the HEXA and HEXB genes driven by a single promoter within the same AAV9 construct, dubbed a bicistronic vector.

Trials 52

Trials Antibody Gene Therapy Gene 52

Roots Analysis

OCTOBER 30, 2023

These RNA based therapeutics play a crucial role in protein production and regulation of gene functions. Self-amplifying RNA (saRNA): Self amplifying RNA is an engineered form of RNA, combining the amplifying genome (native to certain viruses) to the therapeutic gene of interest.

RNA 40

RNA Vaccination Vaccine Development 40

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 40

Antibody Vaccination Vaccine Trials 40

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

The Pharma Data

OCTOBER 21, 2020

Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the pricing of its public offering of 4,687,500 shares of its common stock at a public offering price of $40.00 BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc.

Gene Therapy 40

Gene Therapy Immune Response Sales Gene 40